Skip to content
Review

Abstract 4734: Reduced-Dose Direct Oral Anticoagulant versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Reduced-dose direct oral anticoagulants (DOACs) are increasingly used after left atrial appendage closure (LAAC) in nonvalvular atrial fibrillation (NVAF), but their comparative efficacy and safety versus dual antiplatelet therapy (DAPT) remain uncertain, with no consensus on the optimal post-procedural antithrombotic strategy. Research Question/Hypothesis: We hypothesised that reduced-dose DOAC therapy would reduce device-related thrombosis and thromboembolic events without increasing major bleeding compared with DAPT following LAAC. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) and observational cohorts comparing reduced-dose DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10-15 mg once daily) with DAPT after successful LAAC in adults (≥18 years) with NVAF was conducted by searching PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov through February 2026. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using random-effects models; heterogeneity was assessed with I 2 and χ 2 statistics. Analyses were performed with RevMan 5.4. Results: Seven studies (3 RCTs, 4 cohorts) including 2,126 patients (reduced-dose DOAC = 1,088; DAPT = 1,038) were analysed. Reduced-dose DOAC significantly reduced composite thromboembolic events (RR 0.20, 95% CI 0.10-0.39; I 2 =0%), ischaemic stroke (RR 0.33, 95% CI 0.13-0.80; I 2 =0%), and device-related thrombosis (RR 0.33, 95% CI 0.18-0.60; I 2 =0%) compared with DAPT. The net clinical benefit composite (thromboembolism plus major bleeding) favoured reduced-dose DOAC (RR 0.36, 95% CI 0.19-0.70; I 2 =63%), with apixaban-predominant subgroups showing the strongest effects (RR 0.14, 95% CI 0.05-0.36). Major bleeding was lower (RR 0.54, 95% CI 0.35-0.83; I 2 =0%), any bleeding reduced (RR 0.52, 95% CI 0.30-0.88; I 2 =64%), and minor bleeding trended lower (RR 0.66, 95% CI 0.42-1.02; I 2 =34%), while cardiovascular (RR 0.66, 95% CI 0.23-1.92) and all-cause mortality (RR 0.74, 95% CI 0.42-1.30) did not differ significantly between groups. Conclusion: Reduced-dose DOAC, particularly apixaban-based regimens, represents a favourable antithrombotic strategy after LAAC in NVAF, significantly reducing thromboembolic events, device-related thrombosis, and major bleeding without excess mortality. These findings support reduced-dose DOAC as an effective post-procedural option in appropriately selected patients, though the significant heterogeneity observed in composite and any-bleeding outcomes warrants cautious interpretation and further confirmatory trials.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.